Back Hepatitis C

Hepatitis C

EASL 2012: Promising Findings for Therapeutic Hepatitis C Vaccine TG4040

An investigational hepatitis C virus (HCV) therapeutic vaccine significantly improved the likelihood of sustained response to interferon-based therapy, according to a proof-of-concept study reported at the 47th International Liver Congress (EASL 2012) this week in Barcelona.alt

EASL 2012: Boceprevir a Useful Option for Patients Who Did Not Respond to Earlier Hepatitis C Therapy

A regimen of boceprevir with pegylated interferon and ribavirin achieved cure rates of between 40% and 68% in patients who did not respond to a previous course of hepatitis C therapy, data presented to the 47th International Liver Congress (EASL 2012) in Barcelona last week show.alt

EASL 2012: Simeprevir (TMC435) Improves Response Rates for Difficult-to-Treat Hepatitis C Patients

A combination of simeprevir -- better known as TMC435 -- plus pegylated interferon and ribavirin raised cure rates for genotype 1 hepatitis C patients who did not respond to previous treatment, according to a study presented at the 47th International Liver Congress (EASL 2012) last week in Barcelona.alt

EASL 2012: Abbott Interferon-Free HCV Combinations Show Early Promise for Untreated Patients

Two interferon-free antiviral regimens being developed by Abbott showed high hepatitis C cure rates in small studies of treatment-naive patients presented last week at the 47th International Liver Congress (EASL 2012) in Barcelona.alt

EASL 2012: Telaprevir and Boceprevir Effective but Cause Serious Side Effects in Patients With Cirrhosis

A real-world study of recently approved hepatitis C protease inhibitors in the group of patients who have been told they should not wait for newer, experimental antivirals has shown a much higher rate of serious adverse events and treatment discontinuations than in clinical trials, Christophe Hézode reported on behalf of the French Compassionate Use of Protease Inhibitors in Cirrhotics (CUPIC) cohort study at the 47th International Liver Congress (EASL 2012) in Barcelona on Thursday.alt

EASL 2012: GS-7977 with Interferon/Ribavirin Cures Most Treatment-Naive Hepatitis C Patients in 12 Weeks

Adding GS-7977 to pegylated interferon and ribavirin for 12 weeks led to a sustained response rate of 90% for previously untreated chronic hepatitis C patients with difficult-to-treat genotype 1, researchers reported at the 47th International Liver Congress (EASL 2012) last week in Barcelona.alt

EASL 2012: GS-7977, Daclatasvir, and Asunaprevir Look Good in Interferon-Free Regimens for Hepatitis C

Most previously untreated people with chronic hepatitis C virus (HCV) infection achieved an early cure with an all-oral combination of the HCV NS5A replication complex inhibitor daclatasvir (formerly BMS-790052) plus the nucleotide NS5B polymerase inhibitor GS-7977, researchers reported this week at the 47th International Liver Congress (EASL 2012) in Barcelona. Another study confirmed that daclatasvir plus the HCV protease inhibitor asunaprevir (formerly BMS-650032) produces a long-term cure for a large proportion of difficult-to-treat patients.alt

EASL 2012: Alisporivir + Ribavirin Is Effective for Hepatitis C, but Pancreatitis Remains a Concern

Alisporivir (formerly Debio 025) in interferon-free combinations cured more than 80% of patients with hepatitis C virus (HCV) genotype 2 or 3, researchers reported the 47th International Liver Congress (EASL 2012) last week in Barcelona. The drug has been put on hold, however, due to a small number of recipients developing life-threatening pancreas inflammation.alt

EASL 2012: International Liver Congress Focuses on Hepatitis C Treatment, Metabolic Liver Disease

The 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012) brought together more than 9000 participants this week in Barcelona to discuss the latest research in the field of liver disease.

This year's International Liver Congress is the largest to date, largely reflecting an increased interest in hepatitis C treatment spurred by the development of direct-acting antiviral (DAA) agents.alt